secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2026-08-05T20:43:14+00:00
Accession:  0001104659-26-091188
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q2 2026 net loss narrows to $33.3M; LOQTORZI revenue up 37% YoY to $13.6M
--------------------------------------------------------------------------------

- LOQTORZI net revenue $13.6M in Q2 2026, up 37% YoY from $10.0M and 15% sequentially from $11.8M.
- GAAP net loss from continuing ops $33.3M ($0.22 diluted EPS) vs $44.9M ($0.39) in Q2 2025.
- Non-GAAP net loss $30.1M ($0.19) vs $39.0M ($0.34) in prior year; total net revenue $14.3M.
- R&D expenses fell to $21.4M from $26.3M; SG&A fell to $21.0M from $26.0M on cost reductions.
- Pipeline: tagmokitug and casdozokitug trials enrolling; initial data readouts expected 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/0001104659-26-091188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer